Related resources
Full-text held externally
- PMID: 21040359
- UKPMCID: 21040359
- DOI: 10.1111/j.1463-1318.2010.02439.x
Search for item elsewhere
University researcher(s)
Review of Biomarkers in Colorectal Cancer.
Newton, K F; Newman, W; Hill, J
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2010;.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 21040359
- UKPMCID: 21040359
- DOI: 10.1111/j.1463-1318.2010.02439.x
Abstract
Aim: Advances in molecular technology have resulted the discovery of many putative biomarkers relevant to colorectal cancer (CRC). Method: Literature searches were performed on PubMed and EMBASE using the words 'colorectal cancer', AND 'biomarkers OR markers'. Biomarkers that are either currently in clinical use or having potential clinical use were identified. Results: Most potential markers are in the discovery phase waiting to undergo clinical validation. Plasma Septin-9 gene hypermethylation analysis shows promise as a non-stool based screening tool. DYPD gene hypermethylation and UGT1A1 gene variation have predictive value for side effects and the efficacy of 5-fluoruracil and irinotecan respectively. Mismatch repair protein immunohistochemistry is able to predict response to 5-fluorouracil, and KRAS and BRAF somatic gene mutation status can predict the response to anti-EGFR therapy. Conclusion: Recent advances indicate that the widespread use of biomarkers may herald the next major advance in the diagnosis and management of CRC.